Navigation Links
WebMD Announces Proposed Offering of Convertible Notes
Date:1/5/2011

NEW YORK, Jan. 5, 2011 /PRNewswire/ -- WebMD Health Corp. (Nasdaq: WBMD) today announced that it intends to offer $350 million of Convertible Notes due 2018 in a private placement. WebMD also expects to grant the initial purchaser in the proposed offering an option to purchase up to an additional $50 million aggregate principal amount of notes.  The notes are being offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.  

The notes will be convertible into shares of WebMD's common stock, based on a conversion rate to be determined.  Interest on the notes will be payable semiannually in arrears on January 31 and July 31 of each year, beginning on July 31, 2011.  The notes will mature on January 31, 2018, unless previously repurchased or converted in accordance with their terms prior to such date.  The interest rate, conversion rate, conversion price and other terms of the notes will be determined at the time of pricing of the offering.  

WebMD intends to use up to $100 million of the net proceeds from the sale of the notes to repurchase shares of its common stock, and to use the remainder of the net proceeds for general corporate purposes, which may include acquisitions and additional repurchases of its common stock, and for working capital.

The notes and the common stock of WebMD issuable upon conversion of the notes will not be registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such jurisdiction.

About WebMD

WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers and health plans through our public and private online portals and health-focused publications. More than 80 million unique visitors access the WebMD Health Network each month.

The WebMD Health Network includes WebMD Health, Medscape, MedicineNet, eMedicine, eMedicine Health, RxList, theHeart.org and drugs.com.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements. These statements are based on WebMD's current plans and expectations and involve risks and uncertainties, including those described in our SEC filings.


'/>"/>
SOURCE WebMD
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WebMD Completes Redemption of 3 1/8% Convertible Notes
2. WebMD to Present at the Citi 7th Annual U.S. Small/Mid Cap Conference
3. WebMD Announces 2009 Health Heroes
4. WebMD to Present at the 2009 Citi Investment Research Small and Mid Cap Conference
5. WebMD Health Corp. Announces Intention To Commence Tender Offer To Repurchase Up To 5,700,000 Shares of its Common Stock
6. WebMD Launches New Consumer Health Portal in the U.K.
7. WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders
8. Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
9. RSB Spine, LLC, Announces Record 2010 Revenue Growth
10. Gliknik Announces Completion of Equity Financing
11. BD Announces Webcast of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/4/2016)... NY (PRWEB) , ... December 03, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted its first Swirl: A Wine Tasting Event in New York City, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
Breaking Medicine News(10 mins):